EditorialEditorial

J. Payer

Clin Osteol 2012; 17(3): 75

Osteonecrosis of the jaw associated with bisphospohonate therapy - practical experiencesOriginal contributions

Šenk F., Jirgl L.

Clin Osteol 2012; 17(3): 76-83

At present, bisphosphonates (BPs) are the most common group of antiresorptive drugs used in the treatment of numerous metabolic bone diseases, especially postmenopausal osteoporosis. Adverse effects of these drugs include the risk of development of osteonecro­ sis of the jaw. This dental complication is relatively frequent in intravenous therapy with high doses of BPs in malignancies associated with high bone resorption and hypercalcemia. The article deals with the risk of development of this complication even after admini­ stration of oral BPs in bone disorders to patients at risk of developing osteonecrosis, e.g. due to old age, prolonged exposure...

Renal function in IV bisphosphonate therapy in common practiceReview articles

Bubeníček P., Kasalický P., Rosa J.

Clin Osteol 2012; 17(3): 84-89

Background: Treatment of osteoporosis with bisphosphonates is limited by the level of renal function. The study aimed at determi­ ning the levels of renal function in patients of our center for bone disease in common practice prior to and after IV bisphosphonate therapy, and whether the therapy is associated with decreased renal function. Patients and methods: The study comprised a total of 222 patients (91 % being females; mean age 68 years) receiving IV bisphos­ phonate therapy in a common bone disease center. The group consisted of 95 patients receiving 1-year zoledronate infusions and 127 patients in whom IV ibandronate therapy had been initiated....

Antiepileptics - pathogenetic mechanism of the effect on bone metabolism and requirements for monitoring antiepileptic drug-induced bone conditionsReview articles

Franeková L., Zárubová J., Rovenský J.

Clin Osteol 2012; 17(3): 90-97

Apart from epilepsy, antiepileptic drugs have been used to treat migraine, bipolar disorder and chronic pain. Long-term use of antie­ pileptics is associated with bone conditions such as osteopenia, osteoporosis and osteomalacia. The laboratory findings include nor­ mal or decreased calcium concentration, increased levels of bone remodeling markers, normal or decreased vitamin D concentrations and normal or increased parathormone levels. The most severe forms of bone disease are observed in antiepileptics inducing cyto­ chrome P450 (phenytoin, carbamazepine, phenobarbital, primidone, topiramate > 200 mg/day) and valproate known to be associated...

NEWSInformations

Clin Osteol 2012; 17(3): 99

15th Congress Slovak and Czech OsteologistsAbstracts

Clin Osteol 2012; 17(3): 100-120